MoonLake Immunotherapeuti Company Insiders
MLTX Stock | USD 54.43 0.19 0.35% |
MoonLake Immunotherapeuti's insiders are aggressively selling. The analysis of the overall insider sentiment regarding MoonLake Immunotherapeutics suggests that vertually all insiders are panicking. MoonLake Immunotherapeuti employs about 50 people. The company is managed by 11 executives with a total tenure of roughly 117 years, averaging almost 10.0 years of service per executive, having 4.55 employees per reported executive.
MoonLake Immunotherapeuti's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-10-04 | Simon Sturge | Disposed 171000 @ 53.72 | View | ||
2024-02-29 | Da Silva Jorge Santos | Disposed 4740 @ 55.89 | View | ||
2024-02-27 | Kristian Reich | Disposed 29431 @ 55 | View | ||
2024-02-20 | Kristian Reich | Disposed 10000 @ 57.43 | View | ||
2024-02-16 | Kristian Reich | Disposed 10000 @ 60.15 | View | ||
2024-02-15 | Da Silva Jorge Santos | Disposed 20000 @ 60.18 | View | ||
2024-02-14 | Kristian Reich | Disposed 10000 @ 62.43 | View | ||
2023-12-19 | Matthias Bodenstedt | Disposed 94736 @ 59.22 | View |
Monitoring MoonLake Immunotherapeuti's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
MoonLake |
MoonLake Immunotherapeuti Management Team Effectiveness
The company has return on total asset (ROA) of (0.1332) % which means that it has lost $0.1332 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.168) %, meaning that it created substantial loss on money invested by shareholders. MoonLake Immunotherapeuti's management efficiency ratios could be used to measure how well MoonLake Immunotherapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to rise to -0.1 in 2024. At this time, MoonLake Immunotherapeuti's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.8 M in 2024.Common Stock Shares Outstanding is likely to drop to about 27.8 M in 2024. Net Loss is likely to rise to about (42.7 M) in 2024
MoonLake Immunotherapeuti Workforce Comparison
MoonLake Immunotherapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,353. MoonLake Immunotherapeuti holds roughly 50.0 in number of employees claiming about 2.12% of equities under Health Care industry.
MoonLake Immunotherapeuti Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MoonLake Immunotherapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on MoonLake Immunotherapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MoonLake Immunotherapeuti insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MoonLake Immunotherapeuti Notable Stakeholders
A MoonLake Immunotherapeuti stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MoonLake Immunotherapeuti often face trade-offs trying to please all of them. MoonLake Immunotherapeuti's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MoonLake Immunotherapeuti's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Annett Zippel | Director Culture | Profile | |
Joana Cortez | Director Compliance | Profile | |
Carla Bretes | Director Development | Profile | |
Tino Anthamatten | Market Marketing | Profile | |
Luciana Marques | People HR | Profile | |
Jorge Silva | CEO CoFounder | Profile | |
Nicolas Mosimann | General Counsel | Profile | |
Oliver Daltrop | Chief Officer | Profile | |
Nuala Brennan | Chief Officer | Profile | |
Kristian Reich | CoFounder Officer | Profile | |
Matthias Bodenstedt | Chief Officer | Profile |
About MoonLake Immunotherapeuti Management Performance
The success or failure of an entity such as MoonLake Immunotherapeuti often depends on how effective the management is. MoonLake Immunotherapeuti management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MoonLake management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MoonLake management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.07) | (0.07) | |
Return On Capital Employed | (0.10) | (0.10) | |
Return On Assets | (0.07) | (0.07) | |
Return On Equity | (0.07) | (0.07) |
Please note, the imprecision that can be found in MoonLake Immunotherapeuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MoonLake Immunotherapeutics. Check MoonLake Immunotherapeuti's Beneish M Score to see the likelihood of MoonLake Immunotherapeuti's management manipulating its earnings.
MoonLake Immunotherapeuti Workforce Analysis
Traditionally, organizations such as MoonLake Immunotherapeuti use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MoonLake Immunotherapeuti within its industry.MoonLake Immunotherapeuti Manpower Efficiency
Return on MoonLake Immunotherapeuti Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 881.6K | |
Net Loss Per Executive | 4M | |
Working Capital Per Employee | 10.1M | |
Working Capital Per Executive | 45.8M |
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.